UK Regulatarors Report 30 AstraZeneca Related Blot Clot Incidents

Britain’s drug regulators announced on Thursday that they have identified 30 cases of rare blood clotting events that are linked to the Oxford/AstraZeneca Covid-19 vaccine.

In a statement, the Medicines and Healthcare Products Regulatory Agency (MHRA) still believes that the benefits of AstraZeneca’s COVID-19 vaccine continued to outweigh any potential risks that it has.

According to the British drug watchdog, it has recorded 22 cases of rare brain blood clots and 8 reports of other blood clotting events out of a total of 18.1 million doses of the AstraZeneca shot that had been administered as of March 24.

The new number is 25 more than what the agency disclosed on March 18.

Despite the growing number of rare blood clotting incidents, health authorities still believe that the benefits of the vaccine in the prevention of COVID-19 far outweigh its risk of blood clots.

Unlike other European countries that already suspended or restricted the administration of the vaccine due to its rare adverse effects, the usage of the vaccine would continue.

“On the basis of this ongoing review, the benefits of the vaccines against Covid-19 continue to outweigh any risks and you should continue to get your vaccine when invited to do so,” the British regulator said in its statement.

The MHRA also clarified that has not received any reports of blood clotting cases following the usage of the BioNTech/Pfizer vaccine.


© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.